Navigation Links
Vanda Reports Successful Completion Of Pre-NDA Meeting With FDA On Tasimelteon For The Treatment Of Non-24-Hour Disorder In The Totally Blind
Date:3/25/2013

WASHINGTON, March 25, 2013 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that the company held a pre-NDA meeting with the Division of Neurology Products of the U.S. Food and Drug Administration (FDA) to discuss the regulatory path for filing a New Drug Application (NDA) for tasimelteon, a circadian regulator, for the treatment of Non-24-Hour Disorder (Non-24).  Non-24 is a serious, rare circadian rhythm disorder that affects a majority of totally blind individuals.  Currently there is no FDA approved treatment for Non-24.

At the pre-NDA meeting, the FDA confirmed that the efficacy and safety data proposed by Vanda to be submitted in the tasimelteon NDA for Non-24 is adequate to support filing.  The NDA supporting package that includes data from clinical pharmacology, pre-clinical pharmacology program, chemistry and manufacturing was also deemed adequate to support filing.

"We are pleased with the positive interaction we had with the FDA as we are moving closer to providing a treatment for blind individuals with Non-24," said Mihael H. Polymeropoulos , M.D., President and CEO of Vanda. 

Based on this successful completion of the pre-NDA meeting, Vanda is targeting an NDA submission for tasimelteon in mid-2013.

About Vanda Pharmaceuticals Inc.:
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders.  For more on Vanda, please visit www.vandapharma.com.   

Company Contact:
Jim Kelly
Senior Vice President and Chief Financial Officer
Vanda Pharmaceuticals Inc.
(202) 734-3428

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Vanda Pharmaceuticals to Present at the Cowen and Company 33rd Annual Health Care Conference
2. Vanda Pharmaceuticals Reports Fourth Quarter 2012 and Full Year 2012 Results
3. Vanda Announces Phase IIb/III Clinical Study In Major Depressive Disorder Did Not Meet The Primary Endpoint
4. Vanda Announces Positive Results in the Second Phase III Study (RESET) of Tasimelteon for the Treatment of Non-24-Hour Disorder
5. Vanda Pharmaceuticals to Announce Fourth Quarter 2012 Financial Results on February 12, 2013
6. Vanda Pharmaceuticals Reports Third Quarter 2012 Results
7. Vanda Pharmaceuticals to Participate in Two September Healthcare Investor Conferences
8. Vanda Pharmaceuticals to Announce Second Quarter 2012 Financial Results on August 2, 2012
9. Vanda Pharmaceuticals to Present at the JMP Securities Healthcare Conference
10. Michael Cola Joins the Board of Directors of Vanda Pharmaceuticals
11. Vanda Pharmaceuticals Announces Date of Annual Meeting of Stockholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... GABLES, Fla. , Nov. 20, 2014   ... to become the first U.S. commercial producer of Molybdenum-99 ... a contract with INVAP to design its ... Fla. Mo-99 is the parent isotope of ... medicine procedures worldwide. In 2012, Congress passed legislation making ...
(Date:11/21/2014)... , Nov. 21, 2014  Lexicon Pharmaceuticals, Inc. (Nasdaq: ... its previously announced underwritten public offering of $50,000,000 of ... shelf registration statement. The offering will consist of 49,751,244 ... of $1.005 per share.  Lexicon has also granted the ... additional shares of common stock.  All of the shares ...
(Date:11/18/2014)... 18, 2014 Respiratory Motion and IMI Co ... device and services providers in Japan ... Motion,s innovative respiratory depression monitor, the ExSpiron™. As part ... working together to connect the clinical community in promoting ... of bringing innovative medical devices and new technology to ...
Breaking Medicine Technology:Coqui RadioPharmaceuticals Inks Deal With INVAP 2Lexicon Announces Pricing Of Common Stock Offering 2Lexicon Announces Pricing Of Common Stock Offering 3Prominent Japanese Med Device Provider to be Respiratory Motion's Exclusive Partner for World's #2 Medical Market 2Prominent Japanese Med Device Provider to be Respiratory Motion's Exclusive Partner for World's #2 Medical Market 3Prominent Japanese Med Device Provider to be Respiratory Motion's Exclusive Partner for World's #2 Medical Market 4
... 14 Merrimack Pharmaceuticals,Inc. today announced that enrollment ... 100 patients that evaluates the safety and efficacy ... rheumatoid arthritis (RA). MM-093 is a,recombinant version of ... Phase 2 study is,being conducted at 20 centers ...
... Inc.,(Amex: ILE ) announced today the completion ... II/III Study IT-A-008 investigating the Isolagen,Therapy(TM) for the ... will be administered at seven clinical sites across ... Isolagen Therapy could hold great promise for the,treatment ...
Cached Medicine Technology:Merrimack Pharmaceuticals Completes Enrollment in a Phase 2 Study of MM-093 in Patients with Rheumatoid Arthritis 2Isolagen, Inc. Completes Enrollment in Isolagen Therapy(TM) Phase II/III Acne Scar Study 2Isolagen, Inc. Completes Enrollment in Isolagen Therapy(TM) Phase II/III Acne Scar Study 3
(Date:11/23/2014)... (PRWEB) November 23, 2014 The FDA ... in Common, **FDAnews On-Demand Webinar**, Dec. 11, 2014 ? ... , The FDA’s focus on promotional activities is no ... , Now they're looking at websites, Twitter, journal articles, ... calendar for Thursday, Dec. 11, for On-Demand access to ...
(Date:11/23/2014)... OH (PRWEB) November 23, 2014 Wright ... on behalf of Ohio and West Virginia residents who ... other health disorders due to drinking C8 contaminated ... In Parkersburg, West Virginia. According to the C8 complaints, ... they either worked or lived in at least one ...
(Date:11/23/2014)... November 23, 2014 Today Zane ... for small businesses, announced their new on demand ... of Employer-Provided Health Insurance. , According ... greatest financial risk facing most American families. It ... small and large, when it comes to recruiting ...
(Date:11/22/2014)... (PRWEB) November 23, 2014 A new ... its doors in the downtown Greenville area. Dr. Chelsea ... Greenville , decided to open her own clinic after ... results with the patients. , AlignLife believes that ... tools. With a focus on chiropractic care and rehabilitation ...
(Date:11/22/2014)... PrettyTailor , an outstanding dress company, has ... Customers can buy new dresses at its online shop ... website. , As a matter of fact, PrettyTailor specializes ... provides four types of wedding outfits, including bridesmaid dresses, ... It also provides a variety of occasion dresses, such ...
Breaking Medicine News(10 mins):Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 2Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 3Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 4Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 5Health News:40 C8 Lawsuit Claims Filed By Wright & Schulte LLC Alleged Serious Illness Due To C8 Contaminated Water In Ohio And West Virginia 2Health News:40 C8 Lawsuit Claims Filed By Wright & Schulte LLC Alleged Serious Illness Due To C8 Contaminated Water In Ohio And West Virginia 3Health News:40 C8 Lawsuit Claims Filed By Wright & Schulte LLC Alleged Serious Illness Due To C8 Contaminated Water In Ohio And West Virginia 4Health News:Zane Benefits, Inc. Announces New Webinar on The End of Employer-Provided Health Insurance Now Available On-Demand! 2Health News:AlignLife of Downtown Greenville is Now Open and Accepting New Patients 2Health News:Customers Are Welcome to Shop at PrettyTailor.com 2
... ... Floor Randolph, CHICAGO, April 15 (Photo: ... skeleton outfitted with 73 actual orthopaedic devices used ... or joint problems. Manny dramatically demonstrates medical advances ...
... ... Network, NEW YORK, April ... strategic and business-building,experience, has joined GHG Grey Healthcare Group in the newly ... a WPP company and one of the world,s leading,healthcare communications companies. Ms. ...
... WHAT: A new study reports that inner-city children with ... at levels below current air quality standards. The ... of outdoor pollution levels on asthma symptoms and ... by the National Institutes of Health (NIH) and ...
... cervical cancer cells missed by chemotherapy , , TUESDAY, April ... to radiation and chemotherapy improves results for patients with ... (RU-486, the so-called abortion pill) to chemotherapy kills ovarian ... the conclusions of two reports on new trends in ...
... the 11 Awards Presented is the Inaugural Randy Pausch, PhD Pilot ... ... April 15 The Pancreatic Cancer,Action Network ( http://www.pancan.org ) announced today ... cancer,research. The grant portfolio, topping $1 million in new grants, includes,four Pilot ...
... experts suggest, , , TUESDAY, April 15 (HealthDay News) -- ... after millions of American women stopped using hormone-replacement therapy ... black women. , In fact, the rates ... black women from 2002 through 2004, while they were ...
Cached Medicine News:Health News:Susan Byrne joins GHG Grey Healthcare Group as EVP, Strategy and Business Development, Europe, a Newly-Created Position 2Health News:Air pollution affects respiratory health in children with asthma 2Health News:Extra Drug Improves Rectal Cancer Treatment 2Health News:Extra Drug Improves Rectal Cancer Treatment 3Health News:The Pancreatic Cancer Action Network Announces Its 2008 Research Grant Awards Totaling Over $1 Million in New Research Funding 2Health News:The Pancreatic Cancer Action Network Announces Its 2008 Research Grant Awards Totaling Over $1 Million in New Research Funding 3Health News:The Pancreatic Cancer Action Network Announces Its 2008 Research Grant Awards Totaling Over $1 Million in New Research Funding 4Health News:Breast Cancer Unchanged in Black Women, Despite Drop in HRT Use 2Health News:Breast Cancer Unchanged in Black Women, Despite Drop in HRT Use 3
Omniseal TD mat. Reusable rubber mat for sealing PCR plates. 5 pk....
Inquire...
... heat-resistant, aluminum foil film designed for the ... minimizes evaportaion and vapor loss during thermal ... devices or mats. Its proprietary adhesive ... Compared to other aluminum foils, AlumaSeal ...
Microseal 'F' foil, seals plates for cold storage (or cycling >25l), disposable, pkg of 100...
Medicine Products: